Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29429683 | 1.00 | CYP2D6 (0.49) | CYP2D6ADRA2AADRA1AMEN1MAPK1 | |
| SCHEMBL669891 | 1.00 | CYP2D6 (0.49) | CYP2D6ADRA2AADRA1AMEN1MAPK1 | |
| SCHEMBL895659 | 1.00 | CYP2D6 (0.49) | CYP2D6ADRA2AADRA1AMEN1MAPK1 | |
| SCHEMBL30166162 | 0.85 | CYP2D6 (0.41) | CYP2D6ADRA2AADRA1AMEN1MAPK1 | |
| SCHEMBL3725877 | 0.85 | CYP2D6 (0.41) | CYP2D6ADRA2AADRA1AMEN1MAPK1 | |
| SCHEMBL25180793 | 0.85 | CYP2D6 (0.41) | CYP2D6ADRA2AADRA1AMEN1MAPK1 | |
| SCHEMBL3702590 | 0.85 | CYP2D6 (0.41) | CYP2D6ADRA2AADRA1AMEN1MAPK1 | |
| SCHEMBL30949362 | 0.85 | CYP2D6 (0.41) | CYP2D6ADRA2AADRA1AMEN1MAPK1 | |
| SCHEMBL8119851 | 0.84 | NFE2L2 (0.43) | CYP2D6ADRA2AADRA1AALKNFE2L2 | |
| SCHEMBL1161748 | 0.83 | IDO1 (0.41) | CYP2D6ADRA2AADRA1AMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028352-A1 | MACROCYCLIC IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SUZHOU LANGRUI BIOPHARMACEUTICAL CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
| EP-4585598-A1 | MACROCYCLIC IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Suzhou Langrui Biopharmaceutical Co., Ltd. (CN) | 2025-07-16 | — | — | EP | disclosed |
| CN-117659020-A | Imidazo [1,2-b ] pyridazine derivative, and preparation method and application thereof | 苏州朗睿生物医药有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-117659043-A | Macrocyclic imidazo [1,2-b ] pyridazine derivative and preparation method and application thereof | 苏州朗睿生物医药有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-117624166-A | Triazole derivative and preparation method and application thereof | 苏州朗睿生物医药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20240025908-A1 | COMPOUND USED AS KINASE INHIBITOR AND USE THEREOF | TYK MEDICINES, INC. (CN) | 2024-01-25 | — | — | US | disclosed |
| EP-3967696-A1 | COMPOUND USED AS KINASE INHIBITOR AND APPLICATION THEREOF | TYK Medicines Inc. (CN) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020224626-A1 | COMPOUND USED AS KINASE INHIBITOR AND APPLICATION THEREOF | 浙江同源康医药股份有限公司 | 2020-11-12 | — | — | WO | disclosed |
| US-9879293-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160177354-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | SAFC, INC. | 2016-06-23 | — | — | US | disclosed |
| EP-2462115-B1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | INFINITY PHARMACEUTICALS INC (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20140371456-A1 | Enzymatic Transamination of Cyclopamine Analogs | ROYALTY SECURITY, LLC | 2014-12-18 | — | — | US | disclosed |
| US-8703448-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120083607-A1 | Enzymatic Transamination of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025908-A1 | COMPOUND USED AS KINASE INHIBITOR AND USE THEREOF | ROS1, ALK, RET | CYP2D6 1637/4885ADRA2A 2916/4885ADRA1A 1047/4885 |
| US-20120083607-A1 | Enzymatic Transamination of Cyclopamine Analogs | TKT, TALDO1, BCHE | CYP2D6 554/4885ADRA2A 4133/4885ADRA1A 3775/4885 |
| US-20140371456-A1 | Enzymatic Transamination of Cyclopamine Analogs | TKT, TALDO1, BCHE | CYP2D6 554/4885ADRA2A 4133/4885ADRA1A 3775/4885 |
| US-20260028352-A1 | MACROCYCLIC IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | WEE2, WEE1, ROR1 | CYP2D6 203/4885ADRA2A 1125/4885ADRA1A 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.